Yahoo · Jun 7, 2026
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance.
LG
NYSE · LGNYZ
Ligand Pharmaceuticals Incorporated
Healthcare · Medical - Pharmaceuticals
$0.04
Down-$0.01 (-17.78%)
Updated Aug 16, 2026, 7:36 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 885.69K
- P/E ratio
- 99
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 4.97K
- Avg. volume
- 119.99K
Price performance
LGNYZ price history
1M range · 0 trading sessions · Daily adjusted prices
LGNYZ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest LGNYZ news
The latest Smart Investors Daily articles mentioning LGNYZ.
Stock researchCompany · Overview
LGNYZ research
Overview
Company profile and research snapshot.
Company profile
LIGAND PHARMS GENERAL CVR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- —
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Leerink Partners | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | Oppenheimer | Outperform | — |
| Jul 21, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
